AR088846A1 - COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE DERIVADOS DE 4-PREGENEN-11b-17-21-TRIOL-3,20-DIONA - Google Patents

COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE DERIVADOS DE 4-PREGENEN-11b-17-21-TRIOL-3,20-DIONA

Info

Publication number
AR088846A1
AR088846A1 ARP120104261A ARP120104261A AR088846A1 AR 088846 A1 AR088846 A1 AR 088846A1 AR P120104261 A ARP120104261 A AR P120104261A AR P120104261 A ARP120104261 A AR P120104261A AR 088846 A1 AR088846 A1 AR 088846A1
Authority
AR
Argentina
Prior art keywords
tetradecahydro
glycolyl
phenanthren
cyclopenta
oxo
Prior art date
Application number
ARP120104261A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088846(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR088846A1 publication Critical patent/AR088846A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP120104261A 2011-11-11 2012-11-12 COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE DERIVADOS DE 4-PREGENEN-11b-17-21-TRIOL-3,20-DIONA AR088846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11

Publications (1)

Publication Number Publication Date
AR088846A1 true AR088846A1 (es) 2014-07-10

Family

ID=47179019

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104261A AR088846A1 (es) 2011-11-11 2012-11-12 COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE DERIVADOS DE 4-PREGENEN-11b-17-21-TRIOL-3,20-DIONA

Country Status (24)

Country Link
US (7) US8865691B2 (fr)
EP (2) EP2776040B1 (fr)
JP (2) JP6158201B2 (fr)
KR (2) KR20140095549A (fr)
CN (2) CN104203247B (fr)
AR (1) AR088846A1 (fr)
AU (3) AU2012335590B2 (fr)
BR (2) BR112014011341A2 (fr)
CA (3) CA2855929C (fr)
CL (2) CL2014001244A1 (fr)
CO (2) CO6970598A2 (fr)
ES (1) ES2806603T3 (fr)
HK (2) HK1200367A1 (fr)
IL (2) IL232535B (fr)
IN (2) IN2014CN03903A (fr)
MX (3) MX365859B (fr)
MY (2) MY172227A (fr)
PH (2) PH12014501079B1 (fr)
RU (2) RU2688159C2 (fr)
SG (3) SG10201603766PA (fr)
TW (1) TWI584809B (fr)
UA (2) UA111867C2 (fr)
WO (2) WO2013071009A1 (fr)
ZA (2) ZA201403431B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EA201500651A1 (ru) 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
AR098747A1 (es) * 2013-12-13 2016-06-08 Allergan Inc Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
RU2746083C2 (ru) * 2015-03-05 2021-04-06 Аллерган, Инк. Самоэмульгирующиеся системы доставки лекарств (sedds) для доставки офтальмологического лекарства
CA3037176A1 (fr) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particules, compositions et procedes pour applications ophtalmiques et/ou autres applications
WO2019055028A1 (fr) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. Particules, compositions et procédés pour applications ophtalmiques et/ou autres applications
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (fr) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (fr) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の17α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
CN1157404C (zh) * 1999-10-15 2004-07-14 里奥药物制品有限公司 新的梭链孢酸衍生物
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
JP4619786B2 (ja) * 2002-08-29 2011-01-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性、アレルギー性及び増殖性疾患の治療において糖質コルチコイドミメティックスとして使用するための3−(スルホンアミドエチル)−インドール誘導体
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
CA2562356A1 (fr) * 2004-04-08 2005-10-27 Retmed Pty Ltd Traitement de pathologies ophtalmiques
WO2006017347A2 (fr) * 2004-07-12 2006-02-16 Allergan, Inc. Compositions ophtalmiques et procédés de traitement de conditions ophtalmiques
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP2319517B1 (fr) * 2006-06-01 2013-09-11 Novagali Pharma S.A. Utilisation des promédicaments pour une administration oculaire intrvitréenne
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにcpuユニット
AR069804A1 (es) * 2007-12-21 2010-02-17 Schering Corp Agonistas del receptor glucocorticoide c20- c21 sustituido
CN105147608B (zh) * 2008-06-26 2019-12-10 安特里奥公司 真皮递送
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ

Also Published As

Publication number Publication date
CA2855929C (fr) 2018-03-27
PH12014501079A1 (en) 2014-07-28
JP2014533274A (ja) 2014-12-11
CL2014001243A1 (es) 2014-11-28
US8906892B2 (en) 2014-12-09
PH12014501078A1 (en) 2014-07-28
AU2018200436A1 (en) 2018-02-08
AU2012335590A1 (en) 2014-05-29
CA2855290C (fr) 2017-02-28
US8865691B2 (en) 2014-10-21
JP6216719B2 (ja) 2017-10-18
NZ624920A (en) 2017-06-30
SG11201402225RA (en) 2014-06-27
US20130123226A1 (en) 2013-05-16
EP2776040A1 (fr) 2014-09-17
AU2018200436B2 (en) 2019-10-24
CN104203247B (zh) 2017-06-06
MX2014005679A (es) 2014-12-10
MX2019006877A (es) 2019-08-22
KR20140095548A (ko) 2014-08-01
ZA201403430B (en) 2016-05-25
US20170182062A1 (en) 2017-06-29
JP2014533275A (ja) 2014-12-11
HK1200367A1 (en) 2015-08-07
CA2855290A1 (fr) 2013-05-16
SG11201402247PA (en) 2014-06-27
WO2013071009A1 (fr) 2013-05-16
MX365859B (es) 2019-06-18
CL2014001244A1 (es) 2014-11-14
AU2012335590B2 (en) 2017-10-19
HK1200366A1 (en) 2015-08-07
ZA201403431B (en) 2016-05-25
US20150005519A1 (en) 2015-01-01
IN2014CN03919A (fr) 2015-09-04
CA2991883A1 (fr) 2013-05-16
WO2013071010A1 (fr) 2013-05-16
RU2683775C2 (ru) 2019-04-02
IN2014CN03903A (fr) 2015-10-16
EP2776041A1 (fr) 2014-09-17
UA111867C2 (uk) 2016-06-24
PH12014501078B1 (en) 2014-07-28
KR20140095549A (ko) 2014-08-01
IL232535A0 (en) 2014-06-30
US20130123223A1 (en) 2013-05-16
MX363669B (es) 2019-03-29
MY182222A (en) 2021-01-18
UA116622C2 (uk) 2018-04-25
MY172227A (en) 2019-11-18
CN104185472A (zh) 2014-12-03
JP6158201B2 (ja) 2017-07-05
IL232534A0 (en) 2014-06-30
BR112014011333A2 (pt) 2017-05-02
KR102049615B1 (ko) 2019-11-28
AU2012335589B2 (en) 2017-08-31
TW201325596A (zh) 2013-07-01
CA2991883C (fr) 2020-03-10
US10493082B2 (en) 2019-12-03
EP2776040B1 (fr) 2020-04-22
US20190365786A1 (en) 2019-12-05
CN104185472B (zh) 2017-06-13
RU2014123471A (ru) 2015-12-20
AU2012335589A1 (en) 2014-05-29
SG10201603766PA (en) 2016-07-28
CO6970609A2 (es) 2014-06-13
MX2014005678A (es) 2014-12-10
IL232535B (en) 2019-09-26
ES2806603T3 (es) 2021-02-18
CN104203247A (zh) 2014-12-10
PH12014501079B1 (en) 2014-07-28
CO6970598A2 (es) 2014-06-13
US10188667B2 (en) 2019-01-29
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
US20180147217A1 (en) 2018-05-31
BR112014011333B1 (pt) 2020-04-28
CA2855929A1 (fr) 2013-05-16
US9433631B2 (en) 2016-09-06
TWI584809B (zh) 2017-06-01
BR112014011341A2 (pt) 2017-05-02
US20150057258A1 (en) 2015-02-26
US9717743B2 (en) 2017-08-01
RU2014123472A (ru) 2015-12-20

Similar Documents

Publication Publication Date Title
AR088846A1 (es) COMPOSICIONES FARMACEUTICAS Y METODOS DE USO DE DERIVADOS DE 4-PREGENEN-11b-17-21-TRIOL-3,20-DIONA
CO2017003396A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
NI201500160A (es) Derivados 11-hidroxilo de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor de farnesoid x
AR089004A1 (es) Composiciones farmaceuticas inyectables, metodo, uso
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
AR086399A1 (es) Composiciones estables de povidona-yodo con anti-inflamatorios esteroides o no-esteroides
CL2014000032A1 (es) Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
AR091006A1 (es) Formulaciones de testosterona proliposomal
PE20141676A1 (es) Composiciones de yodo-povidona estable
BR112015000174A2 (pt) método para o tratamento da artrite
EA201990438A1 (ru) Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
DOP2012000325A (es) Derivados de 6,7-dihidro-5h-benzo (7)anulenos, metodos para su preparacion, preparaciones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
CY1120323T1 (el) Φαρμακευτικες συνθεσεις για μειωση επιπλοκων απο οφθαλμικο στεροειδες
UY34899A (es) Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos
PH12019502317A1 (en) Combination theraphy for prostate cancer
PE20151783A1 (es) Dispersion solida de un modulador selectivo de los receptores de progesterona
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
EP2661175A4 (fr) Traitement combiné associant un stéroïde et un antagoniste des récepteurs des glucocorticoïdes
BR112012029697A2 (pt) polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias
NZ630011A (en) Method for treating gynecological diseases
EP3565489A4 (fr) Dispositif et procédé d'administration de compositions à la trompe d'eustache
AR094104A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib

Legal Events

Date Code Title Description
FB Suspension of granting procedure